Physician profile
Carl E Gessner
NPI 1871557116
$1,308.57
in general payments reported to CMS, 2019-2025
23 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $35.81 · 2021: $135 · 2022: $207 · 2023: $176 · 2024: $269 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $151.83 | 2021-2023 | Zeposia |
| Pentax of America, INC. | $151.62 | 2024-2025 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.29 | 2019-2022 | |
| Abbvie INC. | $132.56 | 2019-2024 | |
| Dova Pharmaceuticals | $120.00 | 2019 | |
| Medtronic, INC. | $115.01 | 2021-2024 | Gi Genius |
| Pfizer INC. | $95.91 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.35 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $40.57 | 2021-2022 | |
| Ucb, INC. | $39.97 | 2019 | |
| Cook Medical LLC | $29.92 | 2025 | Hemospray |
| Genzyme Corporation | $29.27 | 2025 | |
| Merck Sharp & Dohme LLC | $27.71 | 2021-2022 | |
| Braintree Laboratories, INC. | $25.84 | 2021-2022 | |
| Endogastric Solutions, INC | $22.42 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.25 | 2024 | Stelara |
| Depuy Synthes Sales INC. | $19.35 | 2020 | |
| Novo Nordisk INC | $18.04 | 2025 | Wegovy |
| Olympus America INC. | $17.80 | 2023 | Endoclot Phs |
| Echosens North America, INC. | $17.42 | 2025 | Fibroscan |
| Evoke Pharma, INC. | $16.26 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.53 | 2023 | Dupixent |
| Qol Medical, LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Gessner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.